JP2016528195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528195A5 JP2016528195A5 JP2016523819A JP2016523819A JP2016528195A5 JP 2016528195 A5 JP2016528195 A5 JP 2016528195A5 JP 2016523819 A JP2016523819 A JP 2016523819A JP 2016523819 A JP2016523819 A JP 2016523819A JP 2016528195 A5 JP2016528195 A5 JP 2016528195A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- antibody
- cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839170P | 2013-06-25 | 2013-06-25 | |
| US61/839,170 | 2013-06-25 | ||
| US201361874241P | 2013-09-05 | 2013-09-05 | |
| US61/874,241 | 2013-09-05 | ||
| US201361884771P | 2013-09-30 | 2013-09-30 | |
| US61/884,771 | 2013-09-30 | ||
| US201361907845P | 2013-11-22 | 2013-11-22 | |
| US61/907,845 | 2013-11-22 | ||
| PCT/US2014/043466 WO2014209802A1 (en) | 2013-06-25 | 2014-06-20 | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129005A Division JP7021153B2 (ja) | 2013-06-25 | 2019-07-11 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528195A JP2016528195A (ja) | 2016-09-15 |
| JP2016528195A5 true JP2016528195A5 (https=) | 2017-07-27 |
| JP6611709B2 JP6611709B2 (ja) | 2019-11-27 |
Family
ID=52142579
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523819A Active JP6611709B2 (ja) | 2013-06-25 | 2014-06-20 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用 |
| JP2019129005A Active JP7021153B2 (ja) | 2013-06-25 | 2019-07-11 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
| JP2022015562A Active JP7356531B2 (ja) | 2013-06-25 | 2022-02-03 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129005A Active JP7021153B2 (ja) | 2013-06-25 | 2019-07-11 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
| JP2022015562A Active JP7356531B2 (ja) | 2013-06-25 | 2022-02-03 | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US9243068B2 (https=) |
| EP (2) | EP3013350B1 (https=) |
| JP (3) | JP6611709B2 (https=) |
| KR (2) | KR20210104166A (https=) |
| CN (1) | CN105492016B (https=) |
| AU (2) | AU2014302812B2 (https=) |
| BR (1) | BR112015032690B1 (https=) |
| CA (2) | CA2916245C (https=) |
| DK (1) | DK3013350T3 (https=) |
| EA (1) | EA036591B1 (https=) |
| ES (1) | ES2782834T3 (https=) |
| IL (1) | IL243301B (https=) |
| MX (1) | MX377858B (https=) |
| NZ (1) | NZ631015A (https=) |
| PL (1) | PL3013350T3 (https=) |
| PT (1) | PT3013350T (https=) |
| SG (2) | SG11201510505VA (https=) |
| WO (1) | WO2014209802A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010129917A2 (en) | 2009-05-08 | 2010-11-11 | Vaccinex, Inc. | Anti-cd100 antibodies and methods for using the same |
| AU2012322721B2 (en) | 2011-10-11 | 2016-05-05 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| US10278984B2 (en) * | 2014-05-02 | 2019-05-07 | Nitor Therapeutics | Guanosine as an immune potentiator mediated through toll receptors |
| US10973843B2 (en) | 2016-01-27 | 2021-04-13 | University Of Maryland, Baltimore | Method for monitoring cancer and for regulation of semaphorin 4D to improve cancer immunotherapy regimens |
| US10358496B2 (en) | 2016-03-01 | 2019-07-23 | Ralf Kleef | Low dose immune checkpoint blockade in metastatic cancer |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| CA3020418A1 (en) * | 2016-04-18 | 2017-10-26 | Faron Pharmaceuticals Oy | Diagnosis of immune_activation using clever-1, tnf-alpha and hla-dr binding agents |
| US10577427B2 (en) | 2016-04-22 | 2020-03-03 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
| WO2017217545A1 (ja) * | 2016-06-16 | 2017-12-21 | 国立大学法人東京大学 | プレキシンの結合調節剤 |
| BR112019001944A2 (pt) | 2016-08-02 | 2019-05-07 | Vaccinex, Inc. | métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia |
| USD889258S1 (en) * | 2016-08-04 | 2020-07-07 | Carolin McKie | Beverage container identification marker kit |
| AU2017326003A1 (en) * | 2016-09-16 | 2019-04-11 | Children's Medical Center Corporation | KLRG1 depletion therapy |
| JP7041136B2 (ja) * | 2016-10-12 | 2022-03-23 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｔｕｓｃ２免疫療法のための方法および組成物 |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| ES2963046T3 (es) * | 2017-03-20 | 2024-03-25 | Vaccinex Inc | Tratamiento del cáncer con un anticuerpo contra la semaforina-4d combinado con un agente modulador epigenético |
| EP3612210A4 (en) | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS |
| CA3061963A1 (en) | 2017-05-05 | 2018-11-08 | Vaccinex, Inc. | Human anti-semaphorin 4d antibody |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| US12312416B2 (en) | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| US12473336B2 (en) | 2018-02-21 | 2025-11-18 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| EP3693380A1 (en) * | 2019-02-11 | 2020-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Dual inhibition of plexin-b1 and plexin-b2 |
| WO2020198572A1 (en) | 2019-03-28 | 2020-10-01 | Vaccinex, Inc. | Semaphorin-4d antagonists for use in cancer therapy |
| IL288779B2 (en) * | 2019-06-21 | 2025-11-01 | Vaccinex Inc | Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy |
| AU2020322474A1 (en) | 2019-08-01 | 2022-03-10 | Vaccinex,Inc. | Combined inhibition of semaphorin-4D and TGFβ and compositions therefor |
| WO2021024020A1 (en) * | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN111158663B (zh) * | 2019-12-26 | 2021-07-02 | 深圳逻辑汇科技有限公司 | 用于处理程序代码中的变量的引用的方法和系统 |
| CN115210252A (zh) | 2020-02-04 | 2022-10-18 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗二硝基苯酚的嵌合抗原受体 |
| CN117597360A (zh) * | 2020-06-25 | 2024-02-23 | 瓦西尼斯公司 | 脑信号蛋白-4d结合分子在rett综合征治疗中的应用 |
| US20230390345A1 (en) * | 2020-08-21 | 2023-12-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination therapy comprising her-2-dc1 vaccine, a probiotic, and semaphorin |
| CN112233123B (zh) * | 2020-09-21 | 2024-05-14 | 广州金域医学检验中心有限公司 | 病理图片中肿瘤间质分类方法、装置、计算机设备及存储介质 |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2023012314A1 (en) * | 2021-08-05 | 2023-02-09 | Lifearc | Anti-plexin-b1 antibodies |
| CN117802242A (zh) * | 2024-01-22 | 2024-04-02 | 深圳慕光生物科技有限公司 | 一种利用sema4d基因预测肿瘤免疫逃避风险的方法 |
| WO2026080818A1 (en) * | 2024-10-10 | 2026-04-16 | Vaccinex, Inc. | Use of anti-semaphorin-4d inhibitory molecules in combination with flt3 ligand to inhibit tumor growth and metastasis |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| CA2286477A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| ATE407206T1 (de) | 1998-11-10 | 2008-09-15 | Univ Rochester | Methoden zu herstellung von genbanken |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| ATE483472T1 (de) | 2002-05-30 | 2010-10-15 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| UA101945C2 (uk) | 2003-05-30 | 2013-05-27 | Дженентек, Инк. | Лікування злоякісного новоутворення за допомогою бевацизумабу |
| AU2004296184B2 (en) | 2003-12-04 | 2010-12-16 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| CA2548282A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| CA2575402A1 (en) * | 2004-08-05 | 2006-02-09 | Genentech, Inc. | Humanized anti-cmet antagonists |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| US7919246B2 (en) | 2005-04-07 | 2011-04-05 | Novartis Vaccines And Diagnostics, Inc. | SEMA4D in cancer diagnosis, detection and treatment |
| ES2971647T3 (es) | 2005-04-15 | 2024-06-06 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| US7919594B2 (en) | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
| AU2008219020B2 (en) | 2007-02-21 | 2013-08-22 | Vaccinex, Inc. | Modulation of NKT cell activity with antigen-loaded CDId molecules |
| CA2710680C (en) | 2007-12-26 | 2018-10-16 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
| AR070134A1 (es) * | 2008-01-10 | 2010-03-17 | Genentech Inc | Agonistas de plexind1 que comprende un fragmento de semaforina 3e(sema3e) y su uso |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010129917A2 (en) | 2009-05-08 | 2010-11-11 | Vaccinex, Inc. | Anti-cd100 antibodies and methods for using the same |
| CA3017298C (en) * | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| NZ605260A (en) | 2010-06-14 | 2013-12-20 | Joseph King Allan | Anti-vegf antibodies and uses thereof |
| SG188285A1 (en) | 2010-09-02 | 2013-04-30 | Vaccinex Inc | Anti-cxcl13 antibodies and methods of using the same |
| MX343640B (es) | 2011-05-13 | 2016-11-15 | Nat Univ Corp Tokyo Medical & Dental Univ | Promotor de osteogenesis. |
| RU2014117952A (ru) | 2011-10-06 | 2015-11-20 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Антитела против sema4a человека, используемые для лечения заболевания |
| AU2012322721B2 (en) | 2011-10-11 | 2016-05-05 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability |
| CA2762446C (en) * | 2011-12-06 | 2021-02-23 | Vaccinex, Inc. | Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| NZ629828A (en) | 2012-03-02 | 2017-05-26 | Vaccinex Inc | Methods for the treatment of b cell-mediated inflammatory diseases |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| CN105408355A (zh) | 2013-01-31 | 2016-03-16 | 瓦克纳斯有限公司 | 用于提高免疫球蛋白a水平的方法 |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| BR112015032690B1 (pt) * | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| US10577427B2 (en) | 2016-04-22 | 2020-03-03 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
| BR112019001944A2 (pt) | 2016-08-02 | 2019-05-07 | Vaccinex, Inc. | métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia |
| EP3585435A4 (en) | 2017-02-22 | 2020-12-16 | Vaccinex, Inc. | EARLY DETECTION OF GLIAL CELL ACTIVATION IN NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISEASES |
-
2014
- 2014-06-20 BR BR112015032690-0A patent/BR112015032690B1/pt active IP Right Grant
- 2014-06-20 JP JP2016523819A patent/JP6611709B2/ja active Active
- 2014-06-20 ES ES14818498T patent/ES2782834T3/es active Active
- 2014-06-20 PL PL14818498T patent/PL3013350T3/pl unknown
- 2014-06-20 KR KR1020217025537A patent/KR20210104166A/ko not_active Ceased
- 2014-06-20 EA EA201690080A patent/EA036591B1/ru unknown
- 2014-06-20 EP EP14818498.9A patent/EP3013350B1/en active Active
- 2014-06-20 US US14/310,848 patent/US9243068B2/en active Active
- 2014-06-20 WO PCT/US2014/043466 patent/WO2014209802A1/en not_active Ceased
- 2014-06-20 PT PT148184989T patent/PT3013350T/pt unknown
- 2014-06-20 KR KR1020167001991A patent/KR102291971B1/ko active Active
- 2014-06-20 CA CA2916245A patent/CA2916245C/en active Active
- 2014-06-20 DK DK14818498.9T patent/DK3013350T3/da active
- 2014-06-20 US US14/892,099 patent/US9828435B2/en active Active
- 2014-06-20 CA CA3098741A patent/CA3098741C/en active Active
- 2014-06-20 MX MX2015017485A patent/MX377858B/es unknown
- 2014-06-20 CN CN201480047166.7A patent/CN105492016B/zh active Active
- 2014-06-20 SG SG11201510505VA patent/SG11201510505VA/en unknown
- 2014-06-20 NZ NZ631015A patent/NZ631015A/en unknown
- 2014-06-20 EP EP19209162.7A patent/EP3656392A1/en active Pending
- 2014-06-20 SG SG10201902380SA patent/SG10201902380SA/en unknown
- 2014-06-20 AU AU2014302812A patent/AU2014302812B2/en active Active
-
2015
- 2015-12-23 IL IL243301A patent/IL243301B/en active IP Right Grant
-
2017
- 2017-08-01 US US15/666,133 patent/US10526414B2/en active Active
-
2019
- 2019-04-23 US US16/392,451 patent/US11078295B2/en active Active
- 2019-07-11 JP JP2019129005A patent/JP7021153B2/ja active Active
- 2019-07-26 AU AU2019208274A patent/AU2019208274A1/en not_active Abandoned
-
2021
- 2021-06-29 US US17/362,020 patent/US12070500B2/en active Active
-
2022
- 2022-02-03 JP JP2022015562A patent/JP7356531B2/ja active Active
-
2024
- 2024-07-18 US US18/777,075 patent/US20250032609A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528195A5 (https=) | ||
| Lazăr et al. | Prognostic significance of tumor immune microenvironment and immunotherapy: novel insights and future perspectives in gastric cancer | |
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| JP2021512914A5 (https=) | ||
| Bell et al. | OX40 signaling in head and neck squamous cell carcinoma: overcoming immunosuppression in the tumor microenvironment | |
| Parmar et al. | Immunotherapy in head and neck squamous cell carcinoma: An updated review | |
| Goel et al. | Cancer immunotherapy in clinical practice—the past, present, and future | |
| RU2019115428A (ru) | Способы лечения рака, включающие связывающие tigit агенты | |
| FI3313441T3 (fi) | Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla | |
| JP2019519499A5 (https=) | ||
| JP2020534250A5 (https=) | ||
| JP2020528750A5 (https=) | ||
| CN108473578A (zh) | 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合 | |
| RU2014111999A (ru) | Антитела к C10RF32 и их применения для лечения рака | |
| JP2022532490A5 (https=) | ||
| JP2016525117A5 (https=) | ||
| FI3455259T3 (fi) | Anti-PD-1-vasta-aineiden ja sädehoidon yhdistelmä syövän hoitoon | |
| KR20220082097A (ko) | 방사선 치료와 조합된 ｐｄ-1 및 ｐｄ-ｌ1에 대한 길항제를 이용하는 암 치료 방법 | |
| JP2018503365A5 (https=) | ||
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| RU2017120063A (ru) | Терапевтические комбинации для лечения неоплазии | |
| JP7548924B2 (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| RU2019104980A (ru) | Анти-icos антитела | |
| JPWO2020067085A1 (ja) | 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬 | |
| Cohen et al. | Therapeutic combinations of immune-modulating antibodies in melanoma and beyond |